Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study

BACKGROUND: BRAF and MEK inhibitors target therapies (TT) and AntiPD1 immunotherapies (IT) are available first-line treatments for BRAF v600 mutant metastatic melanoma patients. ECOG PS (E), baseline LDH (L), and baseline number of metastatic sites (N) are well-known clinical prognostic markers that...

Descripción completa

Detalles Bibliográficos
Autores principales: Marconcini, Riccardo, Fava, Paolo, Nuzzo, Amedeo, Manacorda, Simona, Ferrari, Marco, De Rosa, Francesco, De Tursi, Michele, Tanda, Enrica Teresa, Consoli, Francesca, Minisini, Alessandro, Pimpinelli, Nicola, Morgese, Francesca, Bersanelli, Melissa, Tucci, Marco, Saponara, Maristella, Parisi, Alessandro, Ocelli, Marcella, Bazzurri, Serena, Massaro, Giulia, Morganti, Riccardo, Ciardetti, Isabella, Stanganelli, Ignazio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421680/
https://www.ncbi.nlm.nih.gov/pubmed/36046043
http://dx.doi.org/10.3389/fonc.2022.917999

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421680/
https://www.ncbi.nlm.nih.gov/pubmed/36046043
http://dx.doi.org/10.3389/fonc.2022.917999

Ejemplares similares